HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME: Take the course for this article: Volume 64, Number 9, May 10, 2005 Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zanusso, G. Articles by Monaco, S. Search for Related Content PubMed PubMed Citation Articles by Zanusso, G. Articles by Monaco, S.

Phosphorylated 14-3-3 protein in the CSF of neuroleptic-treated patients

From the Departments of Neurological and Visual Sciences (Drs. Zanusso, Fiorini, Farinazzo, Gelati, Benedetti, Ferrari, Rizzuto, and S. Monaco) and Science and Technology (Drs. Capaldi and H.L. Monaco), University of Verona, Verona, Italy; and Division of Neurology (Dr. Dalla Libera), Thiene, Vicenza, Italy.

Address correspondence and reprint requests to Dr. Salvatore Monaco, Department of Neurological and Visual Sciences, Section of Neurology, Policlinico G.B. Rossi, P.le L.A. Scuro, 10, 37134 Verona, Italy; e-mail: salvatore.monaco{at}mail.univr.it

The authors describe 12 neuroleptic-treated patients with dementia of various etiologies who showed CSF elevation of phosphorylated 14-3-3 and normal tau protein levels. This contrasted with elevated amounts of 14-3-3 , , and unphosphorylated coupled to high tau protein levels in Creutzfeldt–Jakob disease and negative 14-3-3 assay in drug-free patients with dementia. Characterization of CSF 14-3-3 isoforms and determination of tau protein level can help to distinguish different etiologies of dementia.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the May 10 issue to find the title link for this article.

Supported by grants from Fondazione Cariverona 2002 "Neurodegenerative Disorders" and from the Italian Ministry of Health in collaboration with and with the contribution of the Istituto Superiore di Sanità ("Search for Infection-Related Endogenous or Exogenous Factors in the CSF of Patients with Transmissible Spongiform Encephalopathy" and "Study of Pathogenic Mechanisms in Neurodegenerative Disorders for the Diagnosis and Development of Therapeutic Approaches") to Dr. Monaco.

Received November 11, 2004. Accepted in final form January 17, 2005.

This article has been cited by other articles:

				A. Bersano, M. Fiorini, S. Allaria, G. Zanusso, E. Fasoli, M. Gelati, H. Monaco, G. Squintani, S. Monaco, and E. Nobile-Orazio Detection of CSF 14-3-3 protein in Guillain-Barre syndrome Neurology, December 26, 2006; 67(12): 2211 - 2216. [Abstract] [Full Text] [PDF]

				X. Yang, W. H. Lee, F. Sobott, E. Papagrigoriou, C. V. Robinson, J. G. Grossmann, M. Sundstrom, D. A. Doyle, and J. M. Elkins Structural basis for protein-protein interactions in the 14-3-3 protein family PNAS, November 14, 2006; 103(46): 17237 - 17242. [Abstract] [Full Text] [PDF]